For instance, New Zealand guidelines recommend offering GLP1RAs to all patients with HbA1c levels above target, especially when GLP1RA use would provide additional reductions in cardiovascular risk and/or permit reduction or cessation of other therapies that contribute to weight gain or hypoglycemia
This triple-receptor mechanism distinguishes retatrutide from currently approved medicines such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 agonist)
Oral GLP-1 therapies are frequently associated with gastrointestinal side effects, including nausea, diarrhea, constipation, and vomiting
Quality requirements for compounded drugs differ depending on the setting where compounding occurs
Sergey Terushkin, MD, FACS As a bariatric surgeon and weight-loss specialist, Ive watched the evolution of obesity treatment for over a decade
This consultation is particularly important for individuals with pre-existing pancreatic conditions, diabetes complications, or those taking multiple medications